<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579082</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx20171211</org_study_id>
    <nct_id>NCT03579082</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP
      for patients with replase and refractory Diffuse Large B cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized,controlled,prospective,open,multi-center clinical trial,amied to
      evaluate the safety, tolerability,and efficacy of decitabine combined with R±DHAP in replase
      and refractory Diffuse Large B cell lymphoma.A total of 60 patients are planned to be
      enrolled into the study.Patients with diagnosis of replase and refractory Diffuse Large B
      cell lymphoma will be into two groups,and be treated with decitabine pluse R±DHAP or only
      R±DHAP,respectively.The primary end points are objective responder rate(ORR) and time to
      progression(TTP) and the secondary end points include overall survival(OS) and progression
      free survival(PFS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Objective Responder Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TTP</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Time TO Progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R±DHAP + decitabine:
decitabine:10mg/d,ivgtt,d(-5)-(-1);R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Given ivgtt</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>5-Aza-2'-deoxycytidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age:14-65 years;ECOG rate≤2;expected survival≥3 months

          -  patients with Diffuse Large B cell lymphoma diagnoesd by histopathology detection;

          -  patients ever received RCHOP or CHOP chemotherapy but did not receive DHAP

          -  patients never received radiotherapy

          -  patients with no chemotherapy contraindications:hemoglobin ≥ 90g/L,absoluate
             neutrophil count ≥1.5x109/L,blood platelet ≥100x109/L,ALT and AST ≤ 2-fold upper
             normal limit,serum bilirubin ≤1.5-fold upper normal limit,serum creatinine ≤1.5-fold
             upper normal limit,serum albumin ≥ 30g/L,normal serofibrinogen;

          -  at least one measurable nidus;

          -  no other severe diseases conflict with this project,cardiopulmonary function is
             basically normal

          -  the urine or blood pregnancy test of women in childbearing age must be negative in 7
             days before follow-up visit;

          -  applicable for follow-up visit;

          -  no other antitumor adjoint therapy(including antitumor Chinese medicine,immunotherapy
             and biotherapy),but double phosphate anti-bone transfer therapy and other symptomatic
             treatment are acceptable;

          -  understanding this study and assigning informed consent.

        Exclusion Criteria:

          -  rejecting providing blood preparation;

          -  allergic to drug in this study and with metabolic block;

          -  rejecting adopting reliable contraceptive method in pregnancy or lactation period;

          -  uncontrolled internal medicine disease(including uncontrolled diabetes,severe
             incompetence cardiac,lung,liver and pancreas）；

          -  with severe infection;

          -  with primary or secondary central nervous system tumor invasion;

          -  with immunotherapy or radiotherapy contraindication;

          -  ever suffered with malignant tumor;

          -  having peripheral nervous system disorder or dysphrenia;

          -  with no legal capacity,medical or ethical reasons affecting research proceeding;

          -  participating other clinical trials simultaneously;

          -  adopting other anti-tumor medicine excluding this research;

          -  the researchers considering it inappropriate to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first affilliated hospital of zhengzhou university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingzhi Zhang</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department of The First Affilliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Mingzhi Zhang, Pro,Drc</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>The director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>Decitabine</keyword>
  <keyword>ORR</keyword>
  <keyword>TTP</keyword>
  <keyword>OS</keyword>
  <keyword>PFS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

